GlassScriptPhysician profile
Fletcher Lee Collins
NPI 1922825272
$4,346.69
in general payments reported to CMS, 2019-2025
21 companies · $4,244 in 2025
The $4,244 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $103 · 2025: $4,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,228 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,227.68 |
| Education | $119.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $687.04 | 2024-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $489.31 | 2024-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $442.40 | 2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $392.73 | 2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $365.45 | 2025 | |
| Supernus Pharmaceuticals, INC. | $288.07 | 2025 | Qelbree |
| Corium, LLC | $270.24 | 2025 | Azstarys |
| Axsome Therapeutics, INC. | $215.72 | 2025 | Auvelity |
| Neurocrine Biosciences, INC. | $212.78 | 2024-2025 | Ingrezza |
| Lundbeck LLC | $189.11 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $169.16 | 2025 | Uzedy |
| Noven Therapeutics, LLC | $168.27 | 2025 | Xelstrym |
| Collegium Pharmaceutical, INC. | $152.35 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $123.67 | 2024-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $64.29 | 2025 | Cobenfy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Luye Pharma (USA) LTD. | $34.05 | 2025 | Erzofri Extended-Release |
| Janssen Pharmaceuticals, INC | $19.88 | 2024 | Invega Sustenna |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.30 | 2025 | Abilify Maintena |
| Sage Therapeutics, LLC | $15.89 | 2025 | Zurzuvae |
| Owp Pharmaceuticals, INC. | $13.51 | 2025 | Subvenite |
| Ironshore Pharmaceuticals INC. | $13.47 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fletcher Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.